148 related articles for article (PubMed ID: 2696394)
1. Clinical, analytical and pharmacokinetic aspects in cancer chemotherapy with platinum coordination compounds.
Caroli S; Alimonti A; Petrucci F; La Torre F; Dominici C; Castello MA
Ann Ist Super Sanita; 1989; 25(3):487-97. PubMed ID: 2696394
[TBL] [Abstract][Full Text] [Related]
2. [Platinum-based antineoplastic agents: biomedical applications and therapeutic aspects].
Dominici C; Petrucci F; Alimonti A; La Torre F; Cifani A; Caroli S
Ann Ist Super Sanita; 1995; 31(2):289-94. PubMed ID: 8561393
[TBL] [Abstract][Full Text] [Related]
3. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
5. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
6. New techniques in the pharmacokinetic analysis of cancer drugs. II. The ultratrace determination of platinum in biological samples by inductively coupled plasma-mass spectrometry.
McKay K
Cancer Surv; 1993; 17():407-14. PubMed ID: 8137350
[TBL] [Abstract][Full Text] [Related]
7. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
van Hennik MB; van der Vijgh WJ; Klein I; Elferink F; Vermorken JB; Winograd B; Pinedo HM
Cancer Res; 1987 Dec; 47(23):6297-301. PubMed ID: 3315183
[TBL] [Abstract][Full Text] [Related]
10. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
11. [Cisplatin (platidiam) and the prospects for using complex platinum compounds in the clinical chemotherapy of malignant tumors].
Gorbunova VA
Vopr Onkol; 1989; 35(3):325-30. PubMed ID: 2705315
[TBL] [Abstract][Full Text] [Related]
12. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
13. Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.
Tosetti F; Rocco M; Fulco RA; Chiara S; Bruzzone M; Campora E; Esposito M
Anticancer Res; 1988; 8(3):381-6. PubMed ID: 2839099
[TBL] [Abstract][Full Text] [Related]
14. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the platinum analogues in bladder cancer cell lines.
Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
17. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
19. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of carboplatin pharmacokinetics in pediatric oncology by means of inductively coupled plasma mass spectrometry.
Clerico A; Cappelli C; Ragni G; Caroli S; De Ioris MA; Sordi A; Petrucci F; Bocca B; Alimonti A
Ann Ist Super Sanita; 2006; 42(4):461-8. PubMed ID: 17361071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
